{"title": "Epigenetic drugs show promise as antivirals", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/plants_animals/epigenetics.xml", "value": "Epigenetic drugs show promise as antivirals"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2017/08/170815111010.htm"}], "link": "https://www.sciencedaily.com/releases/2017/08/170815111010.htm", "summary": "Some epigenetic pharmaceuticals have the potential to be used as broad spectrum antivirals, according to a new study. The study demonstrated that histone methyltransferases EZH2/1 inhibitors, which are being used in cancer clinical trials, have activity against a variety of viruses, including herpes simplex virus (HSV).", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/plants_animals/epigenetics.xml", "value": "Some epigenetic pharmaceuticals have the potential to be used as broad spectrum antivirals, according to a new study. The study demonstrated that histone methyltransferases EZH2/1 inhibitors, which are being used in cancer clinical trials, have activity against a variety of viruses, including herpes simplex virus (HSV)."}, "published": "Tue, 15 Aug 2017 11:10:10 EDT", "published_parsed": [2017, 8, 15, 15, 10, 10, 1, 227, 0], "id": "https://www.sciencedaily.com/releases/2017/08/170815111010.htm", "guidislink": false}